Gastrointestinal cancer with indeterminate <sup>18</sup>F‑FDG PET/CT findings: Diagnostic efficacy analysis of <sup>68</sup>Ga‑FAPI‑04 PET/MRI

Miao,Jingxuan; Xu,Yifei; Qiao,Feng; Chen,Ni; Khan,Muhammad Imran; Zhao,Ye; Wang,Hui

doi:10.3892/ol.2026.15647

July-2026 Volume 32 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2026 Volume 32 Issue 1

Full Size Image

Article Open Access

Gastrointestinal cancer with indeterminate ¹⁸F‑FDG PET/CT findings: Diagnostic efficacy analysis of ⁶⁸Ga‑FAPI‑04 PET/MRI

Authors:
- Jingxuan Miao
- Yifei Xu
- Feng Qiao
- Ni Chen
- Muhammad Imran Khan
- Ye Zhao
- Hui Wang
View Affiliations / Copyright

Affiliations: Department of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Division of Basic Medical Sciences, Department of Nuclear Medicine, Anhui Medical University, Hefei, Anhui 230032, P.R. China

Copyright: © Miao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 292
|
Published online on: May 13, 2026

https://doi.org/10.3892/ol.2026.15647
Expand metrics +

Abstract

The present prospective study aimed to investigate whether gallium‑68‑labeled fibroblast activation protein inhibitor‑04 (⁶⁸Ga‑FAPI‑04) positron emission tomography (PET)/magnetic resonance imaging (MRI) could provide notably increased diagnostic accuracy, semi‑quantitative parameters, staging capability, diagnostic guidance value and improved clinical benefits compared with fluorine‑18‑labeled fluorodeoxyglucose (¹⁸F‑FDG) PET/computed tomography (CT) in gastrointestinal (GI) cancer with atypical metabolic activity (uncertain ¹⁸F‑FDG imaging results). In total, 22 patients with histopathologically confirmed GI cancer, clinically suspected of recurrence or metastasis, but with atypical/inconclusive ¹⁸F‑FDG PET/CT results, were analyzed. The present study planned to perform ⁶⁸Ga‑FAPI‑04 PET/MRI within 1‑4 days. The diagnostic performance of both tracers was evaluated. Tumor‑to‑background ratio was used to quantify the radiotracer uptake. The present study employed Fisher's exact test to statistically analyze the association between pathological subtypes and changes in tumor staging, as well as treatment decisions indicated by ⁶⁸Ga‑FAPI‑04 PET. The results demonstrated that ⁶⁸Ga‑FAPI‑04 had significantly higher sensitivity compared with ¹⁸F‑FDG in detecting lymph node involvement (100 vs. 89.01%; P=0.001) and distant organ metastases (92.31 vs. 61.54%; P=0.008). Me ⁶⁸Ga‑FAPI‑04 uptake was significantly higher in primary tumors [median, 6.13 (range, 5.71‑7.57) vs. 2.62 (1.82‑3.03); P=0.004], lymph nodes (9.07±2.93 vs. 3.96±1.73; P<0.001) and various metastatic sites (3.31±2.19 vs. 6.87±4.16; P<0.001). The findings indicated that ⁶⁸Ga‑FAPI‑04 has potential advantages in diagnostic efficiency and visual evaluation. Furthermore, ⁶⁸Ga‑FAPI‑04 altered staging in 36.4% (8/22) of patients and refined the treatment strategies for 27.3% (6/22), particularly those with poorly differentiated adenocarcinoma or mucinous carcinoma. For the 22 patients in the present study, the hospital cost for ⁶⁸Ga‑FAPI‑04 PET/MRI was higher compared with that for ¹⁸F‑FDG PET/CT. However, it generated overall benefits that essentially offset the additional costs. By enabling the timely detection of anastomotic recurrence, lymph node metastasis and distant metastasis for prompt intervention, it saved time, reduced the risk of further disease progression, and also minimized some unnecessary medical procedures caused by false‑positive ¹⁸F‑FDG results. These findings suggested that ⁶⁸Ga‑FAPI‑04 PET/MRI is key to enhancing the diagnostic performance for ¹⁸F‑FDG metabolically atypical GI tumors, refining clinical decision‑making and providing economic benefits. This clinical trial was registered at Clinicaltrials.gov with ID NCT06270394 (date of registration, February 20th, 2024; retrospectively registered).

View Figures

View References

1	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI
2	Thrift AP, Wenker TN and El-Serag HB: Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 20:338–349. 2023. View Article : Google Scholar : PubMed/NCBI
3	Rohren EM, Turkington TG and Coleman RE: Clinical applications of PET in oncology. Radiology. 231:305–332. 2004. View Article : Google Scholar : PubMed/NCBI
4	Ruan D, Zhao L, Cai J, Xu W, Sun L, Li J, Zhang J, Chen X and Chen H: Evaluation of FAPI PET imaging in gastric cancer: A systematic review and meta-analysis. Theranostics. 13:4694–4710. 2023. View Article : Google Scholar : PubMed/NCBI
5	Huang D, Wu J, Zhong H, Li Y, Han Y, He Y, Chen Y, Lin S and Pang H: [68Ga]Ga-FAPI PET for the evaluation of digestive system tumors: Systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 50:908–920. 2023. View Article : Google Scholar : PubMed/NCBI
6	Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT and Cheng JD: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 13:1736–1741. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kitajima K, Nakajo M, Kaida H, Minamimoto R, Hirata K, Tsurusaki M, Doi H, Ueno Y, Sofue K, Tamaki Y and Yamakado K: Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: An update. Nagoya J Med Sc. 79:527–543. 2017.PubMed/NCBI
8	Yun M: Imaging of gastric cancer metabolism using 18 F-FDG PET/CT. J Gastric Cancer. 14:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
9	Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, Becker K, Schuster T, Wester HJ, Siewert JR, et al: Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: A comparative analysis. J Nucl Med. 48:1945–1950. 2007. View Article : Google Scholar : PubMed/NCBI
10	Filik M, Kir KM, Aksel B, Soyda Ç, Özkan E, Küçük ÖN, İbiş E and Akgül H: The role of 18F-FDG PET/CT in the primary staging of gastric cancer. Mol Imaging Radionucl Ther. 24:15–20. 2015. View Article : Google Scholar : PubMed/NCBI
11	Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL and Haberkorn U: FAPI PET: Fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 306:e2207492023. View Article : Google Scholar : PubMed/NCBI
12	Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ and Rettig WJ: Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 274:36505–36512. 1999. View Article : Google Scholar : PubMed/NCBI
13	Li M, Younis MH, Zhang Y, Cai W and Lan X: Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: Cancer and beyond. Eur J Nucl Med Mol Imaging. 49:2844–2868. 2022. View Article : Google Scholar : PubMed/NCBI
14	Windisch P, Zwahlen DR, Giesel FL, Scholz E, Lugenbiel P, Debus J, Haberkorn U and Adeberg S: Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: Systematic review. EJNMMI Res. 11:182021. View Article : Google Scholar : PubMed/NCBI
15	Çermik TF, Ergül N, Yılmaz B and Mercanoğlu G: Tumor imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison with 18F-FDG PET/CT in 22 different cancer types. Clin Nucl Med. 47:e333–e339. 2022. View Article : Google Scholar : PubMed/NCBI
16	Chen H, Pang Y, Li J, Kang F, Xu W, Meng T, Shang Q, Zhao J, Guan Y, Wu H, et al: Comparison of [68Ga]Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: A multicenter retrospective study. Eur Radiol. 33:1329–1341. 2023. View Article : Google Scholar : PubMed/NCBI
17	Li C, Tian Y, Chen J, Jiang Y, Xue Z, Xing D, Wen B and He Y: Usefulness of [68Ga]FAPI-04 and [18F]FDG PET/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: A comparative study. Eur Radiol. 33:2779–2791. 2023. View Article : Google Scholar : PubMed/NCBI
18	Şahin E, Elboğa U, Çelen YZ, Sever Ö N, Çayırlı YB and Çimen U: Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. Eur J Radiol. 142:1098672021. View Article : Google Scholar : PubMed/NCBI
19	Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Tripathi M, ArunRaj ST, Sarswat S and Bal C: Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 48:1915–1931. 2021. View Article : Google Scholar : PubMed/NCBI
20	Liu H, Yang X, Liu L, Qu G and Chen Y: Comparison of 18 F-FDG and 68 Ga-FAPI-04 uptake in postoperative Re-evaluation of gastric, duodenal, and colorectal cancers. Clin Nucl Med. 48:304–308. 2023. View Article : Google Scholar : PubMed/NCBI
21	Liu X, Liu H, Gao C and Zeng W: Comparison of 68Ga-FAPI and 18F-FDG PET/CT for the diagnosis of primary and metastatic lesions in abdominal and pelvic malignancies: A systematic review and meta-analysis. Front Oncol. 13:10938612023. View Article : Google Scholar : PubMed/NCBI
22	Wass G, Clifford K and Subramaniam RM: Evaluation of the diagnostic accuracy of FAPI PET/CT in oncologic studies: Systematic review and metaanalysis. J Nucl Med. 64:1218–1224. 2023. View Article : Google Scholar : PubMed/NCBI
23	Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA; WHO Classification of Tumours Editorial Board, : The 2019 WHO classification of tumours of the digestive system. Histopathology. 76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
24	Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, Jäger D, Mier W and Haberkorn U: Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 59:1415–1422. 2018. View Article : Google Scholar : PubMed/NCBI
25	Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, et al: Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 47:1820–1832. 2020. View Article : Google Scholar : PubMed/NCBI
26	Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, Hu F and Lan X: 68Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 63:81–88. 2022. View Article : Google Scholar : PubMed/NCBI
27	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017.PubMed/NCBI
28	Hill M, Cunningham D, MacVicar D, Roldan A, Husband J, McCready R, Mansi J, Milan S and Hickish T: Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol. 11:2273–2278. 1993. View Article : Google Scholar : PubMed/NCBI
29	Pang Y, Zhao L, Luo Z, Hao B, Wu H, Lin Q, Sun L and Chen H: Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 298:393–402. 2021. View Article : Google Scholar : PubMed/NCBI
30	Qiu L, Lan L, Liu H, Deng J and Chen Y: 68Ga-FAPI PET/CT Detected Non-FDG-Avid gastric stromal tumor. Clin Nucl Med. 47:226–227. 2022. View Article : Google Scholar : PubMed/NCBI
31	Sun Y, Xu J, Qiao Y, Zhang J, Pan H, Xu X and Song S: Assessing the Value of 68Ga-FAPI PET/CT in gastric mucinous adenocarcinoma or signet ring cell carcinoma. Radiol Imaging Cancer. 6:e2301952024. View Article : Google Scholar : PubMed/NCBI
32	Fan C, Guo W, Su G, Chen B and Chen H: Widespread metastatic gastric Signet-ring cell carcinoma shown by 68Ga-FAPI PET/CT. Clin Nucl Med. 46:e78–e79. 2021. View Article : Google Scholar : PubMed/NCBI
33	Li X, Ma W, Wang M, Quan Z, Zhang M, Ye J, Li G, Zhou X, Ma T, Wang J, et al: 68Ga-FAPI-04 PET for surveillance of anastomotic recurrence in postoperative patients with gastrointestinal cancer: A Comparative study with 18F-FDG PET. Mol Imaging Biol. 25:857–866. 2023. View Article : Google Scholar : PubMed/NCBI

Journals